News Channels

20 Jun 2018 Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
20 Jun 2018 Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management
19 Jun 2018 Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
19 Jun 2018 Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
19 Jun 2018 Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
19 Jun 2018 Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
19 Jun 2018 Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrop
19 Jun 2018 Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
19 Jun 2018 Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
19 Jun 2018 Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
19 Jun 2018 How many PD-1 and PD-L1 checkpoint inhibitors do we need?
19 Jun 2018 Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar
19 Jun 2018 Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
19 Jun 2018 Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
19 Jun 2018 Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference
19 Jun 2018 Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
19 Jun 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
19 Jun 2018 Idorsia is initiating REACT - Phase 3 registration study with clazosentan
19 Jun 2018 Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B
19 Jun 2018 Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top